Biotech firm Compass Pathways' operating income beats Q3 analyst expectations

COMPASS Pathways

04/11/2025 11:47

Overview

Compass Pathways Q3 net loss driven by non-cash warrant liabilities adjustment

Company accelerates COMP360 commercialization plans by 9-12 months after FDA discussions

Operating income for Q3 beats analyst expectations

Outlook

Company accelerating commercial launch of COMP360 by 9-12 months

COMP360 9-week data from COMP006 expected in Q1 2026

COMP360 26-week data from COMP006 expected in early Q3 2026

Result Drivers

R&D - Expenses were $27.3 million for the three months ended September 30, 2025, compared with $32.9 million during the same period in 2024. T

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$1.44
Q3 Net Income
-$137.71 mln
Q3 Operating Income
Beat
-$40.53 mln
-$42.70 mln (8 Analysts)
Q3 Operating Expenses
$40.53 mln
Q3 Pretax Profit
-$137.94 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Compass Pathways PLC is $14.00, about 57.5% above its November 3 closing price of $5.95

Press Release: ID:nBw3fCSJha

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)